Trial Profile
A Phase II Study of Navarixin (MK-7123) in Combination With Pembrolizumab (MK-3475) in Participants With Selected Advanced/Metastatic Solid Tumors
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 01 Jul 2022
Price :
$35
*
At a glance
- Drugs Navarixin (Primary) ; Pembrolizumab (Primary)
- Indications Adenocarcinoma; Colorectal cancer; Non-small cell lung cancer; Prostate cancer; Solid tumours
- Focus Adverse reactions; Therapeutic Use
- Sponsors Merck Sharp & Dohme Corp.
- 24 Jun 2021 Status changed from active, no longer recruiting to completed.
- 24 May 2021 Planned End Date changed from 15 May 2021 to 7 Jun 2021.
- 24 May 2021 Planned primary completion date changed from 15 May 2021 to 7 Jun 2021.